The CAR targets are neo-antigens present on the cell surface of adenocarcinomas and more than 90% of ovarian cancer cells. T cells or NK cells with this CAR will seek and bind to the targeted cancer cells via the CAR and signal the immune cell to kill these dangerous cells. We are also researching how to use these CAR- immune cells to recruit the patient’s own immune system to join the attack on targeted cancers by disrupting the solid tumour microenvironment.